Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics (MDNA) is a clinical-stage immunotherapy company at the forefront of developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs). With a mission to lead in the development and commercialization of targeted ECs and superkines, Medicenna aims to revolutionize treatment for a broad range of cancers and immune-mediated diseases. The company leverages its expertise and collaborates with world-class researchers to create unique superkines.
Medicenna's innovative approach allows these superkines to function either as standalone short or long-acting therapeutics or to be fused with pro-apoptotic proteins. This fusion precisely delivers potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment, and cancer stem cells, sparing healthy cells from harm. Additionally, these superkines can be fused with antibodies to create novel 'immunocytokines' or combined with other treatment modalities.
Currently, Medicenna is engaged in various promising projects. A notable recent achievement includes the characterization of its tumor-targeting and activatable T-MASK platform, designed to enhance tumor accumulation and tolerability of potent immune modulators. This innovation was presented at a significant conference on November 3, 2023.
As Medicenna continues to advance its pipeline of targeted treatments, it remains committed to transforming the therapeutic landscape for cancer and immune-related conditions. The company's financial health is supported by strategic partnerships and a focus on groundbreaking research and development.
Medicenna Therapeutics (NASDAQ: MDNA) reported its Q3 results, highlighting progress in its clinical programs, including the Phase 1/2 ABILITY study of MDNA11. The company initiated patient dosing in September 2021 and received IND clearance to expand the trial to the U.S. and other regions. Financially, Medicenna had CAD 26.7 million in cash, allowing operations through 2022. However, the net loss for Q3 2021 increased to CAD 8.2 million, attributed to heightened R&D expenses for MDNA11 and costs from its NASDAQ listing.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announces that CEO Dr. Fahar Merchant will present a corporate overview at Stifel’s Virtual Healthcare Conference on November 15, 2021, from 10:00-10:30 a.m. ET. The event aims to provide insights into Medicenna's clinical-stage immunotherapy developments, including MDNA11 and MDNA55, targeted towards enhancing cancer treatment. Details and a link for the webcast will be available on the company's Investor Relations website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will host a conference call and live webcast on November 12, 2021, at 8:30 AM ET to discuss its second quarter 2022 financial results and operational highlights. Interested participants can join by calling (877) 407-9716 (US) or (201) 493-6779 (internationally) using conference ID: 13723601, or by accessing the live webcast at Medicenna's website. The event will also feature an archive of the call after its conclusion.
Medicenna is a clinical stage immunotherapy company focused on innovative cancer treatments.
Medicenna Therapeutics Corp. (NASDAQ/TSX: MDNA) announced FDA clearance for its investigational new drug (IND) application to expand the Phase 1/2 ABILITY study of MDNA11 to U.S. clinical sites. The ABILITY study evaluates MDNA11, a long-acting 'beta-only' IL-2 super-agonist, aimed at treating advanced solid tumors. Preliminary safety and biomarker data are expected by year-end 2021, while initial efficacy data will be available in mid-2022. Approximately 80 patients will participate, with the study designed for both monotherapy and combination therapy with a checkpoint inhibitor.
Medicenna Therapeutics Corp. (MDNA) announced promising preclinical results for MDNA11, a novel IL-2 super-agonist, at the AACR-NCI-EORTC conference. In non-human primates, MDNA11 showed no typical IL-2 safety issues while inducing robust anti-cancer immune cell expansion. Murine studies indicated 100% tumor control when combined with anti-PD1 therapy. The ongoing Phase 1/2 ABILITY study continues to evaluate MDNA11's efficacy in patients with advanced solid tumors, with preliminary safety and biomarker data expected by year-end 2021.
Medicenna Therapeutics announced the results of its annual shareholder meeting, held on September 23, 2021. The company welcomed Dr. John H. Sampson to its Board of Directors, highlighting his extensive experience in clinical trials and immuno-oncology. All nominated directors were elected with over 97% support from shareholders. PricewaterhouseCoopers LLP was appointed as the company's auditor. A total of 51.408% of shares were represented at the meeting, underpinning strong shareholder engagement.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that its leadership will participate in the Next-Gen Cytokine Therapeutics Summit on September 22, 2021. CEO Dr. Fahar Merchant will present on "Evolutionary IL-2 Superkines" and moderate a panel on cytokine therapies' future. CMO Dr. Mann Muhsin will join a discussion on overcoming challenges in cytokine therapeutics. Medicenna develops novel immunotherapies, including IL-2 Superkine, MDNA11, and IL-4 Empowered Superkine, MDNA55, the latter being in clinical trials for brain cancer.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced the issuance of U.S. Patent No. 11,117,943 for methods to treat various cancers using IL-2 Superkines like MDNA11. The patent enhances the company’s intellectual property portfolio, focusing on the differentiated affinity of MDNA11 for the IL-2 receptor beta. The patent’s term extends until at least 2032. Medicenna has an exclusive worldwide license for the patent and has initiated a Phase 1/2 ABILITY Study for MDNA11. This significant development aims to bolster the company’s value creation strategy.
Medicenna Therapeutics has initiated dosing patients in the Phase 1/2 ABILITY study for its novel IL-2 super-agonist, MDNA11, targeting advanced solid tumors. This trial will assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity with a focus on CD8 T cell and NK cell proliferation. Preliminary safety and biomarker data are anticipated by year-end 2021, while efficacy readouts will follow throughout 2022. The study will enroll at least 80 patients across multiple regions, including the US and Canada, expanding the potential for MDNA11 in treating refractory cancers.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) has announced key presentations for September 2021, featuring CEO Dr. Fahar Merchant. The company will participate in various virtual investor conferences, starting with the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, followed by a panel discussion on September 14. Additional presentations include the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20 and the Cantor Virtual Global Healthcare Conference on September 30. For more details, visit Medicenna's Investor Relations.
FAQ
What does Medicenna Therapeutics specialize in?
What are superkines?
How does Medicenna's T-MASK platform work?
What are empowered cytokines (ECs)?
What recent achievements has Medicenna made?
What is the company's mission?
How does Medicenna ensure the safety of its treatments?
What are immunocytokines?
How does Medicenna collaborate with other researchers?
What is the financial outlook for Medicenna?
